German Breast Group Investigators
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
17.10.2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
17.10.2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators